EGFR is phosphorylated at Ty845 in hepatocellular carcinoma (Q40238980)

18 September 2017

title

EGFR is phosphorylated at Ty845 in hepatocellular carcinoma (English)

1 reference

18 September 2017

0 references

3

Michael S Torbenson

1 reference

18 September 2017

Rajesh Kannangai

1

1 reference

18 September 2017

Fikret Sahin

series ordinal

2

1 reference

18 September 2017

publication date

25 August 2006

1 reference

18 September 2017

1 reference

18 September 2017

volume

19

1 reference

18 September 2017

issue

11

1 reference

18 September 2017

page(s)

1456-1461

1 reference

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

STAT 1alpha/1beta, STAT 3 and STAT 5: expression and association with c-MET and EGF-receptor in long-term cultures of human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

Epidermal growth factor receptor: mechanisms of activation and signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

Trans-activation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

Malignant transformation and EGFR activation of immortalized mouse liver epithelial cells caused by HBV enhancer-X from a human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

7 January 2021

Epidermal growth factor- and hepatocyte growth factor-receptor activity in serum-free cultures of human hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

7 January 2021

Modulation of hepatic acute phase gene expression by epidermal growth factor and Src protein tyrosine kinases in murine and human hepatic cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

7 January 2021

Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

7 January 2021

Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

7 January 2021

Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

7 January 2021

Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800665

7 January 2021

10.1038/MODPATHOL.3800665

Identifiers

DOI

1 reference

Dimensions Publication ID

18 September 2017

1025007104

0 references

1 reference